One year until Seoul Congress
It has already been one year since my Presidential term started at the end of the 2014 Vancouver Congress, and this means it is now one year until the 2016 Seoul Congress.
CINP have undergone dramatic changes during the year and I would like to share with you the summary of our activities, decisions and discussion at the EC meetings etc.
One of the major changes is a format change of our biennial Congress. At the EC meeting in December 2014, we decided to shorten the Congress period to 3 full days (Sunday 3rd to Tuesday 5th of July) including the “Welcome & Award Ceremony” on Sunday evening. MECI International, a Korean PCO, was selected to organize this Congress.
I am pleased to report we received 112 symposium proposals by the deadline of 27th February. The quality of submitted proposals was very high, which ensured a very competitive selection. After impartial and careful review at the ISPC meeting in April 2015 we finally selected 27 very attractive symposia. We also chose 7 prestigious Plenary Lecturers who have subsequently been invited to present their top level scientific findings. I am also pleased to inform you that the percentage of woman speakers among all speakers has increased greatly, which reflects our policy.
IJNP – Change of Publisher to Oxford University Press and Open Access
The publisher of IJNP is now Oxford University Press, and to serve global researchers’ needs better, IJNP is now published as an “Open Access Journal”. This is a very big change for CINP and beneficial to CINP Members as they are entitled to $700 discount of Open Access charges (submission fee for members is $1500 and for non members is $2200) and I encourage CINP members to submit their papers in IJNP.
CINP CNS Drug Development Action Plan
In facing the crisis of psychotropic drug development, CINP convened meetings in Munich (2013) and in Vancouver (2014) with representatives from Academia, Industry and Regulatory (FDA, EMA and PMDA). We held a series of discussions and published the importance of Private Public Partnerships (PPPs) and 10-point Action Plan in IJNP (2015,1-16) and also a Commentary in Nature Reviews Drug Discovery (Vol.13:871-872, 2014)
CNS Drug Innovation Summit in Tokyo
To promote the 10-point Action Plan especially focusing on establishment of PPPs system to encourage psychotropic drug development, we held a two-day CNS Drug Innovation Summit in April 2015 in Tokyo. The open Symposia session on the first day, inviting Dr. Potter of NIMH, Prof. Kapur of IMI NEWMEDS, CINP Officers and key persons of Japanese and global mega pharma companies as speakers, attracted more than 300 participants, and on the second day we held the closed Working Group session with the themes of “biomarker”, “large scale global clinical trials” and “pre-competitive collaboration”, where we had significant discussion toward PPPs in psychotropic drug development. Both open and closed programs were highly rated by participants and we have decided to continue the discussion and present the findings at a special symposium at the 30th World Congress in Seoul 2016.
Thematic Meeting in Dublin
On 4th – 6th June 2015 we had the Thematic Meeting on “Stress, inflammation and depression: focus on novel antidepressant targets” in Dublin organized by our Past President, Prof. Brian Leonard. The meeting was very successful with more than 300 participants including many young scientists. There were lively lunchtime poster sessions and many vigorous discussions regarding inflammation and depression. The meeting concluded on Saturday 6th June with a well attended Educational Session. Please click below to read the on-line programme from this meeting.
I will continue to do my best to contribute to the activities of CINP over the coming months with the 30th CINP World Congress in Seoul, opening just one year from now. I would like to ask for your participation at the Congress and will look forward to welcoming you personally to Seoul in July 2016.